China Medical System Announced Collaboration And License Agreement With Incyte For Selective Oral Smallmolecule JAK1 Inhibitor Povorcitinib

Author: Charles Gross | April 01, 2024 06:40am

China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 31 March 2024, the Group through a wholly-owned subsidiary of the Company– a dermatology medical aesthetic company (“CMS Skinhealth”) entered into a Collaboration and License Agreement (the “License Agreement”) with Incyte (NASDAQ:INCY) (“Incyte”), a global biopharmaceutical company, for selective oral smallmolecule JAK1 inhibitor povorcitinib (the “Product”) for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN) and asthma and chronic spontaneous urticaria.

Posted In: INCY